P 16

Drug Profile

P 16

Alternative Names: P-16; P16 -13therapeutics; Peptide P-16

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer 13therapeutics
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Toll-like receptor 4 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Atherosclerosis; Inflammatory bowel diseases

Most Recent Events

  • 20 Jul 2016 Early research in Atherosclerosis in USA (unspecified route)
  • 20 Jul 2016 Early research in Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top